In Vivo Antibacterial Activity of Acetazolamide.
Antimicrob Agents Chemother
; 65(4)2021 03 18.
Article
em En
| MEDLINE
| ID: mdl-33495225
ABSTRACT
Vancomycin-resistant enterococci (VRE) represent a major public health threat that requires the development of new therapeutics. In the present study, acetazolamide (AZM) was evaluated against enterococci. It inhibited different enterococcal strains tested at clinically achievable concentrations. Moreover, AZM outperformed linezolid, the drug of choice for VRE infections, in two in vivo VRE mouse models-murine colonization-reduction and VRE septicemia. Collectively, these results indicate that AZM warrants consideration as a promising treatment option for VRE infections.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Infecções por Bactérias Gram-Positivas
/
Enterococos Resistentes à Vancomicina
Limite:
Animals
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article